A large body of evidence underscores the adverse effect of long-term exposure to ambient particulate matter (PM) air pollution on respiratory health ([@b9-ehp-117-1420]; [@b21-ehp-117-1420]). Among adults in Switzerland, we have previously demonstrated cross-sectionally that residents of more polluted areas have lower lung function ([@b2-ehp-117-1420]). More recently, we presented evidence from the same population-based cohort \[Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA)\] that decreasing exposure to airborne PM attenuated the average age-related decline in lung function. The associations were strongest for respiratory function tests reflecting small-airway function, namely, FEF~25--75~ \[forced expiratory flow between 25% and 75% of forced vital capacity (FVC)\] ([@b19-ehp-117-1420]). Similar results from studies following interventions such as building bypasses for congested traffic routes ([@b12-ehp-117-1420]; [@b22-ehp-117-1420]) or banning environmental tobacco smoke (ETS) exposure ([@b20-ehp-117-1420]; [@b38-ehp-117-1420]) showed that the improvements in air quality were accompanied by a decrease in cardiopulmonary mortality and an improvement in respiratory symptoms and lung function. However, it is still unknown whether all subjects benefit equally from a reduction in air pollution.

Variation in genes mediating the pathobiological effect of air pollution in the lung may codetermine the degree to which a person benefits from better air quality. Experimental evidence indicates that PM alters expression of tumor protein gene *p53*, cyclin-dependent kinase inhibitor 1A gene (*p21*), and the cyclin D1 gene (*CCND1*) and subsequently affects cell proliferation and apoptosis of lung fibroblasts, lymphocytes, and alveolar epithelial cells ([@b4-ehp-117-1420]; [@b15-ehp-117-1420]; [@b42-ehp-117-1420]; [@b49-ehp-117-1420]; [@b50-ehp-117-1420]). PM is furthermore well known to induce oxidative stress in the airways ([@b31-ehp-117-1420]). In fact, the expression of all three gene candidates, *p53*, *p21*, and *CCND1*, in bronchial epithelial cells and lung fibroblasts seems to be regulated in part by redox-dependent mechanisms ([@b25-ehp-117-1420]; [@b48-ehp-117-1420]; [@b55-ehp-117-1420]).

The tumor suppressor p53, a nuclear transcription factor, binds to response elements in the promoter region of many genes and plays a pivotal role in apoptosis. It induces up-regulation of the expression of many pro-apoptotic genes and down-regulation of anti-apoptotic genes ([@b43-ehp-117-1420]). CCND1 (cyclin D1) is known to promote cell proliferation through cell cycle G1--S phase transition. The protein p21 (also known as Waf1 or Cip1) is a direct functional counterpart of CCND1 and an important downstream effector of p53 action that negatively regulates cell proliferation. *CCND1*, *p21*, and *p53* all harbor polymorphisms of hypothesized functional relevance that have been extensively studied in the context of cancer ([@b14-ehp-117-1420]; [@b35-ehp-117-1420]; [@b57-ehp-117-1420]). In this study, we examined whether these polymorphisms modified the degree to which the age-related FEF~25--75~ decline was attenuated by reduced exposure to PM with aerodynamic diameter ≤ 10 μm (PM~10~).

Materials and Methods
=====================

SAPALDIA cohort study population
--------------------------------

The study design and methodology of SAPALDIA have been described in detail elsewhere ([@b1-ehp-117-1420]; [@b37-ehp-117-1420]). In 1991, health examinations focusing on respiratory health status were conducted in 9,651 adults (18--60 years of age) randomly selected from population registries of eight environmentally diverse areas of Switzerland. Ethical approval was obtained from the Swiss Academy of Medical Sciences and the Regional Ethics Committees. Written informed consent was obtained from all participants before health examination and biological sample collection at both surveys. Nonparticipation at follow-up and missing information on covariates led to the exclusion of participants for the present study \[see Supplemental Material, Figure 1 and Table 2 available online (doi:10.1289/ehp.0800430. S1 via <http://dx.doi.org>)\]. In summary, of the 9,651 subjects who initially participated at baseline (SAPALDIA1), 1,604 had died, left Switzerland, or refused to participate at the follow-up examination (SAPALDIA2). Of 8,047 cohort participants remaining, 5,732 completed the interview questionnaire and spirometry at both the baseline and follow-up surveys. Participants were excluded from the analysis (*n*= 1,406) if they had lived for \< 1 year at their last residential address at follow-up, could not be assigned home outdoor PM~10~ concentrations, or did not provide blood samples for DNA extraction or if the genetic analysis of their sample was unsuccessful. Thus, the present study sample included 4,326 participants with available blood samples and genotype data and complete data from both surveys on spirometry, smoking history, PM~10~ exposure, and residential history during follow-up.

Lung function assessment
------------------------

Identical spirometer devices (model 2200, SensorMedics Corp., Yorba Linda, CA, USA) and protocols were used at baseline and follow-up examinations, and their comparability was assessed before the follow-up study ([@b27-ehp-117-1420], [@b29-ehp-117-1420]). Details of these measurements have been described elsewhere ([@b1-ehp-117-1420]; [@b18-ehp-117-1420]). Briefly, three to eight forced expiratory lung function maneuvers were performed by each participant to obtain a minimum of two measures of FEF, FVC, forced expiratory volume in the first second (FEV~1~), and FEF~25--75~ that were considered acceptable according to [@b3-ehp-117-1420] criteria. Expiratory flow measures were taken from the same flow-volume curve. For each participant, the rate of change in lung function was defined as the difference in each parameter between the two examinations (measurement at follow-up minus measurement at baseline), divided by the participant-specific follow-up time (in nontruncated years).

Selection of genetic variants
-----------------------------

We selected the same common, well-studied, and potentially functional candidate single-nucleotide polymorphism (SNP) in *CCND1* \[proline-to-proline substitution at amino acid 242 (P242P), rs9344\] that we evaluated in our previous research on the interaction of *CCND1* with oxidative stress in breast and colon cancer ([@b13-ehp-117-1420]; [@b46-ehp-117-1420]). We selected one additional common SNP in the *CCND1* gene (rs667515) based on a pilot study involving haplotype-tagging polymorphisms in *CCND1* and their association with accelerated lung function decline in a subsample of the SAPALDIA cohort (unpublished observations). In addition, we examined SNPs in two other important cell cycle control genes that have been repeatedly assessed in cancer association studies and are reported to have a functional effect: *p53* \[arginine-to-proline substitution at amino acid 72 (R72P), rs1042522\] ([@b6-ehp-117-1420]) and *p21* \[serine-to-arginine substitution at amino acid 31 (S31R), rs1801270\]([@b36-ehp-117-1420]).

Genotpying
----------

DNA was extracted from EDTA-buffered whole blood as previously described ([@b1-ehp-117-1420]). Genotyping strategy used was fluorescent 5′-nuclease real-time polymerase chain reaction (TaqMan, Applera Europe, Rotkreuz, Switzerland) methodology using ABI Prism 7900 sequence detection system (ABI, Rotkreuz, Switzerland). The SNP-specific primers and locked nucleic acid (LNA) dual-labeled fluorogenic probes were designed by Sigma Proligo (Evry, France). SNP-specific probes and primers were as follows: rs1042522, 5′-CTGCTCCCCuC/G3CGTGGC-3′, forward 5′-ACTGAAGACCCAGGTCCA-3′, reverse 5′-GCCGGTGTAGGAGCT-3′; rs1801270, 5′-GCTGAGuC/A3CGCGAC-3′, forward 5′-TGCCGCCGCCTCTT-3′, reverse 5′-GATGCAGCCCGCCATTAG-3′; rs667515, 5′-AGCTCCCTTGCuG/C3 CCC-3′, forward 5′-TGGCTTCAT\_ C A G A T G A C A A C -3′, reverse 5′-AACCTGGGCTTCTCCAA-3′; rs9344, 5′-TGTGACCCuA/G3GTAAGTGA-3′, forward 5′-ACGCTTCCTCTCCAGAG_3′, reverse 5′-CAAGGCTGCCTGG-3′. A 10% random sample of all DNA samples was regenotyped, and all geno types were confirmed. The genotype call rate was \> 99%.

Individual residential PM~10~ exposure assessment
-------------------------------------------------

Air pollution exposure assessment has been described in detail elsewhere ([@b19-ehp-117-1420]; [@b34-ehp-117-1420]). We estimated PM~10~ exposure for each participant according to residential history using a hybrid exposure model incorporating Gaussian dispersion (from PolluMap model, version 2.0; [@b34-ehp-117-1420]) and geoinformation based on data on seasonal, meteorologic, and geographic annual emission characteristics from various source categories (e.g., traffic, industrial, regional, and agricultural activities) ([@b34-ehp-117-1420]). Hourly concentrations of PM~10~ were simulated with a spatial resolution of 200 × 200 m grid cells for 1990 and 2002. Annual average PM~10~ exposure concentrations during follow-up were estimated for each residential address with the help of an algorithm that allowed interpolation of modeled values on the basis of historical trends in central-site measurements between 1990 and 2002. Evaluation of dispersion model predictions using a total of 57 PM~10~ Swiss central-site monitors has been described elsewhere ([@b34-ehp-117-1420]). Based on the validated dispersion model, each subject was assigned an annual PM~10~ concentration every year between 1990 and 2002. For that purpose, modeled PM~10~ concentrations were averaged over the year to obtain annual averages for each grid cell. Each participant's residential history was coded using the geographic information system data. Assignment of individual PM~10~ exposure was performed by matching address codes with annual concentrations derived from the grid cells generated by the dispersion model.

The exposure variable used for the present study was the difference in the annual average PM~10~ exposure between 2002 and 1991. It was calculated for each participant as follows: average home outdoor PM~10~ concentration in the 12 months before the baseline examination was subtracted from the corresponding average concentration in the 12 months before the follow-up examination, and this difference was divided by the mean time of follow-up (in nontruncated years). In our previous study ([@b19-ehp-117-1420]), we used two exposure indexes: *a*) the difference in the annual average exposure between 2002 and 1991 (the index used in the present study ) and *b*) the "interval exposure," defined as the sum of the annual exposures for each subject for each year of follow-up between their examinations. Because of the high correlation (*R*^2^ \> 0.9) between these two exposure variables, we were unable to single out the superior measure in our previous report. Both indices showed similar associations with change in lung function ([@b19-ehp-117-1420]).

Collection of data on covariates
--------------------------------

Information on relevant covariates known or likely to determine lung function decline, such as age, height, smoking history, ETS exposure, occupational exposure, and education level, was gathered in a computer-assisted, individually administered interview based on the European Community Respiratory Health Survey questionnaire ([@b11-ehp-117-1420]). Current and past smoking habits, exposure to ETS, and occupational exposure to dust and fumes were assessed with the same questions at both surveys. Participants who reported smoking \< 20 packs of cigarettes and using \< 360 g of tobacco in their lifetime at both time points were defined as never-smokers. Cumulative cigarette exposure of participants was assessed by pack-years smoked before the first examination and pack-years smoked during follow-up. Participants were asked not to smoke in the hour before the examination, and smoking was validated by measuring the carbon monoxide concentration in exhaled breath using an EC 50 Micro-Smokerlizer (Bedfont Scientific, Rochester, UK). Atopic status was assessed at baseline using skin prick tests (Phazet; Pharmacia, Uppsala, Sweden) for eight common inhalant allergens: dog epithelium; cat fur; pollen of timothy grass, *Parietaria*, and birch; the house dust mite *Dermatophagoides pteronyssinus*; and the molds *Alternaria tenuis* and *Cladosporium herbarum* ([@b37-ehp-117-1420]; [@b54-ehp-117-1420]). Atopy was defined by an adjusted mean wheal diameter ≥ 3 mm to at least one allergen.

Statistical analysis
--------------------

We inferred *CCND1* haplotypes from unphased genotype data using PHASE 2.1 algorithm software \[see Supplemental Material, Table 1 (doi:10.1289/ehp.0800430.S1)\] ([@b51-ehp-117-1420]). Hardy-Weinberg equilibrium was tested using STATA gtab command for global κ-statistic testing (STATA version 10; StataCorp, College Station, TX, USA). All four SNPs were in Hardy-Weinberg equilibrium. We obtained Lewtonin's linkage disequilibrium (LD) metric D′using STATA command pwld for pairwise LD. Descriptive analyses of the lung function parameters, PM~10~, smoking, socioeconomic variables, and other relevant covariates have been described previously and in detail in different SAPALDIA cohort study reports ([@b1-ehp-117-1420]; [@b19-ehp-117-1420]; [@b24-ehp-117-1420]). We compared baseline characteristics of the cohort participants included in this study (*n* = 4,326) with subjects participating only at baseline as well as with cohort participants excluded from this analysis because information on genotype or covariate data was missing.

Results are presented as the estimated effect of a 10-μg/m^3^ decrease in the annual average PM~10~ exposure over the follow-up period (ΔPM~10~) on the average attenuation of the annual decline in FEF~25--75~.

The association between ΔPM~10~ and the average annual rate of lung function decline had been previously assessed using mixed linear model analysis, and selection of relevant covariates was based on this previous investigation ([@b19-ehp-117-1420]): age at baseline (SAPALDIA1), age^2^, sex, height, parental smoking during childhood reported at baseline, sine and cosine function of day of examination to control for seasonal effects, level of education at baseline, change in level of education, Swiss nationality, self-reported occupational exposure to dust and occupational exposure to fumes at SAPALDIA1 and SAPALDIA2 (yes/no), smoking status at follow-up (never, former, or current), pack-years up to SAPALDIA1, pack-years between SAPALDIA1 and -2, cigarettes per day at SAPALDIA1 and -2, atopy, body mass index (BMI) at SAPALDIA1, change in BMI, interaction between the two BMI variables, and baseline PM~10~ exposure. Random effects were included to adjust for clustering of residuals within area and were assumed to be independent between the areas and to have an exchangeable correlation structure. To estimate main effects of gene variants of *CCND1*, *p21*, and *p53* and rate of lung function decline, we used the same mixed model with random area effects additionally adjusted for ΔPM~10~. To estimate modification of the ΔPM~10~ effect on average lung function decline by genotype, we introduced interaction terms between ΔPM~10~ and genotypes into the above-described covariate-adjusted mixed linear models independently for each SNP. Also, for each SNP we evaluated three different genetic models (codominant, dominant, and recessive) because previous cancer association studies were not conclusive about the underlying genetic model of the SNP effects. The codominant model assumes that the gene effect depends on the number of alleles in a dose-dependent manner, the dominant model assumes that the gene effect depends on the presence of at least one of two high-risk alleles, and the recessive model assumes that the gene effect depends on the presence of both high-risk alleles. The three genetic models required different coding of genotypes. For each SNP we present the genetic model with the smallest interaction term *p*-value. We obtained effect estimates for the association between ΔPM~10~ and average annual lung function decline in genotype subgroups by creating genotype- specific PM~10~ exposures variables that we introduced into separate covariate-adjusted mixed linear models. Analyses were conducted using SAS release 9.1 (SAS Institute Inc., Cary, NC, USA) and STATA version 10. *p*-Values \< 0.05 were interpreted as statistically significant for main and interaction effects. *p*-Values presented as main *p*-values in the tables are not corrected for multiple testing. Nevertheless, Bonferroni-corrected significance level (α = 0.05 divided by the number of tests) is indicated in tables and figures as appropriate.

Results
=======

Population characterization
---------------------------

[Table 1](#t1-ehp-117-1420){ref-type="table"} describes the general characteristics of the study population (*n* = 4,326), including relevant predictors of lung function. This is a population consisting mostly of Caucasians. At follow-up participants were more likely to be women and less likely to be smokers than were non-participants. Participants tended to gain weight, give up smoking, and reduce exposure to dust or fumes at work or to ETS \[for details, see Supplemental Material, Table 2 (doi:10.1289/ehp.0800430.S1)\].

In 2002, 87% of the participants were living in the same area as in 1991, and 54% had the same address. In general, individual home outdoor concentrations of PM~10~ declined during the follow-up period ([Table 1](#t1-ehp-117-1420){ref-type="table"}), as previously described in detail ([@b19-ehp-117-1420]; [@b34-ehp-117-1420]). The median decline between examinations for subjects included in this analysis was 5.8 μg/m^3^ (interquartile range, 4.2--7.3 μg/m^3^). Mean decline was greatest for participants living in urban areas and lowest in alpine areas.

Mean lung function for the cohort was within the range of predicted values for the general population and declined during the follow-up period ([Table 1](#t1-ehp-117-1420){ref-type="table"}). The mean ± SD annual change in mid FEF~25--75~ during the 11-year follow-up period was −74.1 ± 70.3 mL/year in men and −68.9 ± 58.9 mL/year in women included in this analysis.

The main effects of the investigated genetic variants on change in lung function are described in more detail in Supplemental Material, Table 3 (doi:10.1289/ehp.0800430. S1). Briefly, we observed no statistically significant associations of the polymorphisms either with change in FEF~25--75~ or with FEV~1~ or FVC.

Modification of the ΔPM~10~ effect on aver-age decline in lung function by genotype
-----------------------------------------------------------------------------------

As previously reported ([@b19-ehp-117-1420]), a 10-μg/m^3^ decline in average annual home outdoor PM~10~ concentration over an 11-year period (ΔPM~10~) reduced the annual rate of decline in FEF~25--75~ on average by 11.2 mL/year or 16%. Here we report statistically signifi cant modifications of this association of ΔPM~10~ with FEF~25--75~ decline by three of the four genetic variants investigated: *CCND1* P242P \[*p*-value for interaction (*p*~int~) = 0.017\], *CCND1* rs667515 (*p*~int~ = 0.006), and *p53* R72P (*p*~int~ = 0.016). [Figure 1A](#f1-ehp-117-1420){ref-type="fig"} and [Table 2](#t2-ehp-117-1420){ref-type="table"} present results for the association of ΔPM~10~ with the aver-age annual change in FEF~25--75~ within genotype and diplotype strata for the entire study population; for data for never-smokers, see [Figure 1B](#f1-ehp-117-1420){ref-type="fig"} and Supplemental Material, Table 4 (doi:10.1289/ehp.0800430.S1). Equivalent to the previously reported main effect of ΔPM~10~ ([@b19-ehp-117-1420]), the genotype-specific results we observed in the entire study popu lation were comparable to those in never-smokers. The A allele for *CCND1* P242P reduced the attenuating effect estimate of ΔPM~10~ on FEF~25--75~ decline in a codominant manner. A 10 μg/m^3^ decline in PM~10~ over an 11-year period was associated with an average attenuation of annual decline in FEF~25--75~ of 6.0 mL/year \[95% confidence interval (CI), −4.54 to 16.54\] in participants with an AA genotype, 13.7 mL/year (5.38--22.06) in heterozygous AG participants, and 21.3 mL/year (10.57--32.08) in participants with a GG genotype.

For the *CCND1* rs667515 SNP, the beneficial ΔPM~10~ effect was most pronounced in participants homozygous for the minor allele (CC genotype) and attenuated annual FEF~25--75~ decline in this subgroup by 28.83 mL/year (95% CI, 15.60--42.07) compared with 10.39 (3.24--20.47) and 11.83 (1.32--19.47) among GG and GC genotypes, respectively. This effect modification thus followed a recessive genetic model.

For the *p53* R72P SNP, the observed effect modification followed a codominant model. ΔPM~10~ was associated with an aver-age attenuation of annual FEF~25--75~ decline by an average of 17.4 mL/year (95% CI, 8.95--25.78) in GG genotypes (Pro/Pro) and by an average of 11.6 mL/year (2.65--20.61) in CG genotypes (Arg/Pro) but no attenuation in CC genotypes (Arg/Arg).

*CCND1* haplotypes 2 and 3, but not 1 and 4, were also statistically significant modifiers of the ΔPM~10~ association with FEF~25--75~ decline. In participants exhibiting the *CCND1* haplotype 3 (CG/CG) on both alleles (representing the combination of the single SNP alleles associated with the greatest lung function attenuation), the effect estimate for attenuation of FEF~25--75~ decline associated with ΔPM~10~ was 30.9 mL/year (95% CI, 17.21--44.58) compared with 11.92 (3.40--20.44) and 10.28 (1.22--19.35) among subjects with the CG haplotype in one or none of their alleles ([Table 2](#t2-ehp-117-1420){ref-type="table"}).

Genotype-specific ΔPM~10~ effect estimates for the attenuation of the average annual decline in FEV~1~ and FVC are presented in Supplemental Material, Table 5 (doi:10.1289/ehp.0800430.S1). For FEV~1~ decline, effect modification by genotypes was comparable to that seen for FEF~25--75~ decline. Again, effect modification was strongest for the *CCND1* rs667515 SNP and for *CCND1* haplo-type3 \[see Supplemental Material, Table 5 (doi:10.1289/ehp.0800430.S1)\] We observed no modification of the ΔPM~10~ effect on FVC decline for any of the SNPs or haplotypes.

Discussion
==========

Understanding the pathways by which PM~10~ damages lung structures and identifying susceptible subjects are important steps in managing the public health challenges of anthropogenic ambient air pollution. In this study, we present novel evidence that genetic polymorphisms in the cell fate controlling genes, *p53*, *p21*, and *CCND1* may modify the degree to which adults benefit from improved air quality. If confirmed by independent studies, the results are of public health relevance. The observed difference between genotype subgroups with regard to ΔPM~10~ effects on average lung function decline ranged between 11 mL/year and 21 mL/year for FEF~25--75~. This difference compares with the observed excess mean annual decline in FEF~25--75~ of 18 mL and 14 mL per pack per day smoked during follow-up by, respectively, male and female SAPALDIA participants who smoked at baseline (modeled according to [@b18-ehp-117-1420]). This difference in lung function decline may seem small in absolute terms and from an individual perspective, but even slight shifts in the population distribution of lung function can substantially increase the prevalence of subjects exhibiting respiratory function below clinical thresholds. In addition, lung function is known to be a strong and independent predictor of overall mortality ([@b26-ehp-117-1420], [@b28-ehp-117-1420]).

The mechanisms by which air pollutants induce harmful changes in bronchial tissue and ultimately lead to respiratory symptoms and clinically relevant respiratory dysfunction have been investigated. It seems well established that PM directly increases oxidative stress ([@b17-ehp-117-1420]), activates the expression of proinflammatory cytokines (e.g., tumor necrosis factor α, nuclear factor-κβ, and interleukin-8) ([@b47-ehp-117-1420]) and induces the homing of inflammatory cells such as neutrophils, alveolar macrophages, and dendritic cells, thus resulting in inflammation of the lung ([@b5-ehp-117-1420]; [@b8-ehp-117-1420]; [@b32-ehp-117-1420],[@b33-ehp-117-1420]; [@b41-ehp-117-1420]). The toxic effects of PM are further enhanced by bronchial tissue injuries and increased epithelial permeability ([@b39-ehp-117-1420]).

Our results are in line with more recent *in vitro* experiments with different types of bronchial cell lines demonstrating that PM induces cell proliferation arrest and apoptosis in exposed cells ([@b4-ehp-117-1420]; [@b15-ehp-117-1420]; [@b49-ehp-117-1420]; [@b50-ehp-117-1420]; [@b53-ehp-117-1420]; [@b56-ehp-117-1420]). Air pollutants or cigarette smoke, both exhibiting oxidative properties, specifically alter the expression levels of tumor suppressor genes such as *p53* and *p21* and of the cell cycle control gene *CCND1* in human and rodent *in vitro* bronchial cell culture models. Although *p53* and *p21* expression has been consistently shown to be increased upon PM exposure ([@b4-ehp-117-1420]; [@b15-ehp-117-1420]; [@b25-ehp-117-1420]; [@b42-ehp-117-1420]; [@b45-ehp-117-1420]; [@b49-ehp-117-1420]; [@b50-ehp-117-1420]; [@b55-ehp-117-1420]; [@b56-ehp-117-1420]), *CCND1* expression has been reported to be either inhibited (via *p21* activation) ([@b45-ehp-117-1420]; [@b56-ehp-117-1420]) or increased \[*p53*-driven N-terminal C-Jun kinase (*cJUN*) activation\] ([@b4-ehp-117-1420]; [@b16-ehp-117-1420]; [@b25-ehp-117-1420]). Such variations in the expression of cell cycle genes mediate the adaptive cellular response to changes in environmental exposure. They might well be the starting point of PM~10~-induced pathologic changes in morphology and in the type and number of lung fibroblasts and bronchial epithelial cells. Activation of cell proliferation processes may help to maintain intact airways even in the presence of environmental toxins, as suggested by genetic ablation of *p21* in mice, which conferred protection against cigarette-smoke--induced lung inflammation and injury ([@b55-ehp-117-1420]). Aspects of bronchial tissue remodeling represent key features of pathologic changes in the etiology of most airway disorders. However, how proliferation and apoptosis relate to airway remodeling in general remains poorly understood and is likely to be disease specific.

Three of the four polymorphisms investigated here have been studied before, mainly in cancer studies, and allelic functional differences have been proposed. The functional consequence of *p53* R72P polymorphism was studied in detail. The Arg72-allele (G-allele) of *p53* is more active at inducing apoptosis than is the *p53* Pro72-allele. In fact, Pro72 is part of a PXXP motif known to be critical in binding of a *p53*-specific inhibitory protein, iASPP (inhibitory member of the apoptosis- stimulating protein phosphatase family) ([@b6-ehp-117-1420]). Along the line of the proposed functional consequence of this genetic variant, meta-analysis results have recently shown that the homozygous Pro/Pro genotype showed a proproliferative effect and was associated with increased gastric cancer risk ([@b57-ehp-117-1420]). In our association study, we observed the most pronounced benefits of ΔPM~10~ with regard to FEF~25--75~ decline in subjects with one or two Arg72-alleles, which are expected to induce apoptosis more potently than the Pro72-allele. In contrast, homozygous carriers of the Pro72-allele did not appear to benefit from the improvement in air quality.

The functional studies of the common *CCND1* polymorphism P242P showed a modification of the alternative splicing events in exon 4 because the G-to-A substitution alters the consensus sequence of the splicing donor site ([@b7-ehp-117-1420]; [@b23-ehp-117-1420]). As recently reported by three meta-analyses, the homozygous AA genotype was associated with increased risk of various types of cancer ([@b35-ehp-117-1420]; [@b44-ehp-117-1420]; [@b52-ehp-117-1420]). The A-allele of the *CCND1* 870G\>A (P242P) polymorphism, a proposed genetic risk factor for lung cancer, was previously associated with impaired cell cycle regulation and accumulation of DNA damage in the airway ([@b10-ehp-117-1420]; [@b40-ehp-117-1420]). In our association analysis, we observed that homo- or heterozygous G-allele carriers benefited more from the decrease in PM~10~ exposure than did homozygous A-allele carriers. The association of the second *CCND1* (−7006G\>C) SNP with cancer or any other outcome has not been investigated previously. Its functional consequence, if any, might be regulatory because it is situated upstream of the *CCND1* gene. But it is also possible that this SNP is in high linkage with a yet unknown functional *CCND1* variant, just as it is also in high LD with the *CCND1* P242P variant.

The polymorphism S31R in the *p21* gene was shown to be located in the DNA-binding zinc finger motif and thus has been thought to alter the function of the *p21* protein ([@b36-ehp-117-1420]). However, results of cancer studies for this SNP have been inconsistent with regard to the size and direction of relative risk estimates ([@b14-ehp-117-1420]), and we observed no interaction between this SNP and ΔPM~10~ on lung function decline.

Thus, the cancer-promoting *p53* and *CCND1* alleles seem to reduce the benefit of improved air quality on respiratory function. Only limited epidemiological data exist on the association of *p53*, *p21*, or *CCND1* SNPs with respiratory diseases such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD). The polymorphisms we evaluated in *p53* and *p21* have previously been associated with smoking-related COPD. Compared with healthy smokers, the cancer risk allele of *p53* (Pro72-allele), and the *p21* Arg31-allele were overrepresented in COPD patients ([@b30-ehp-117-1420]). The extrapolation of observed associations with cancer to expected associations with lung function is not straightforward. The present findings and our interpretation of them should be considered as exploratory in nature and need confirmation in independent studies. The relative impacts of cell proliferation and apoptosis on different cell types in the lung and on respiratory function must be further investigated by experimental studies.

The strengths of the present study are its prospective design, its rather large sample size, and detailed characterization of the study participants, as well as the availability of individual air pollution exposure history since 1990. We were thus able to adjust lung function decline for most of the potential confounders. Nonetheless, information on some relevant confounders such as dietary antioxidant intake and physical activity was collected only at follow-up. Lacking data on the degree of genetic admixture of the Swiss general population is an additional drawback. However, we expect little bias due to genetic admixture, because the prevalence of several polymorphisms studied in the cohort did not vary across the three major Swiss language groups. We assessed a very limited number of carefully selected candidate polymorphisms; for some of the SNPs and haplotypes, and especially for the *p21* SNP and *CCND1* haplotype 4, statistical power to detect effect estimation was very limited. A more comprehensive assessment of gene variants in the apoptosis pathway and genes regulating apoptosis in lung tissue needs to be addressed in future larger studies. Nevertheless, even for the small number of genetic variants investigated, multiple testing represents a limitation in the interpretation of the present results. Consistency of the associations across genes involved in cell cycle control, as well as across various lung function outcomes, diminishes the likelihood of chance findings, as does the strength of the observed *p*~int~ values.

Finally, participation at follow-up and in this present study was not complete, so participation bias cannot be excluded. However, because we observed comparable results in all subjects and in never-smokers and in the absence of different effects between men and women, the lower participation rate in men and smokers is not likely to have caused bias.

In conclusion, our results suggest that even at low to moderate levels of air pollution, such as in Switzerland, some but not all persons benefit from improved air quality. Given the novelty of the finding and the limitations inherent to this study, the results need independent confirmation. Future studies must address additional issues. First, gene variants relevant to cell cycle control must be studied more comprehensively. Second, it is of interest to know whether this novel candidate pathway might determine susceptibility to both improvements and declines in air quality.

Supplemental Material is available online (doi:10.1289/ehp.0800430.S1 via <http://dx.doi.org/>)
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###### 

Characteristics of the study population: SAPALDIA cohort.

  Characteristic                                                                                          Participants (*n* = 4,326)
  ------------------------------------------------------------------------------------------------------- ----------------------------
  Female (%)                                                                                              53.0
  Swiss nationality (%)                                                                                   87.7
  Educational level in 2002 (professional education or higher, %)                                         27.9
  Increase in educational level between surveys (%)                                                       17.9
  Age in 1991 \[mean ± SD (years)\]                                                                       41.3 ± 11.2
  Height \[mean ± SD (cm)\]                                                                               169.3 ± 8.8
  BMI in 1991 \[mean ± SD (kg/m^2^)\]                                                                     23.7 ± 3.6
  BMI change \[mean ± SD (kg/m^2^)\]                                                                      2.1 ± 2.2
  Smoking                                                                                                 
   Never-smokers in 1991 (%)                                                                              48.4
   Never-smokers in 2002 (%)                                                                              49.3
   Smoking quitters during follow-up (%)                                                                  8.1
   Current smokers in 1991 (%)                                                                            29.3
   Current smokers in 2002 (%)                                                                            21.9
   No. of pack-years for current smokers in 2002 \[median (IQR)\]                                         26.7 (14.0--42.6)
   Cigarettes per day for current smokers in 1991 \[median (IQR)\]                                        20 (10--25)
   Cigarettes per day for current smokers in 2002 \[median (IQR)\]                                        15 (7--20)
  Passive smoking and occupational exposure (%)                                                           
   ETS exposure in never-smokers in 1991                                                                  13.1
   ETS exposure in never-smokers in 2002                                                                  7.7
   Father or mother smoked during childhood                                                               56.1
   Workplace exposure to dust and fumes in 1991                                                           30.3
   Workplace exposure to dust and fumes in 2002                                                           13.2
   Atopy in 1991                                                                                          22.3
  Change in average individual home outdoor PM~10~ exposure[a](#tfn2-ehp-117-1420){ref-type="table-fn"}   
   All areas (*n* = 4,326)                                                                                −5.8 (−7.3 to −4.2)
   Basel area (*n* = 486)                                                                                 −8.0 (−9.1 to −6.9)
   Wald area (*n* = 889)                                                                                  −4.5 (−4.8 to −3.9)
   Davos area (*n* = 318)                                                                                 −3.0 (−3.1 to −2.8)
   Lugano area (*n* = 568)                                                                                −12.1 (−13.5 to −10.8)
   Montana area (*n* = 431)                                                                               −4.0 (−4.2 to −3.7)
   Payerne area (*n* = 595)                                                                               −5.0 (−5.3 to −4.6)
   Aarau area (*n* = 689)                                                                                 −6.4 (−6.8 to −5.8)
   Geneva area (*n* = 350)                                                                                −6.2 (−7.3 to −5.7)
  Lung function in 1991 \[mean ± SD (L)\][b](#tfn3-ehp-117-1420){ref-type="table-fn"}                     
   FVC in women                                                                                           3.82 ± 0.61
   FVC in men                                                                                             5.30 ± 0.82
   FEV~1~ in women                                                                                        3.07 ± 0.55
   FEV~1~ in men                                                                                          4.11 ± 0.72
   FEF~25--75~ in women                                                                                   3.07 ± 1.00
   FEF~25--75~ in men                                                                                     3.79 ± 1.29
  Annual change \[mean ± SD) (mL/year)\][b](#tfn3-ehp-117-1420){ref-type="table-fn"}                      
   FVC in women                                                                                           −20.79 ± 34.11
   FVC in men                                                                                             −29.17 ± 45.47
   FEV~1~ in women                                                                                        −31.88 ± 25.72
   FEV~1~ in men                                                                                          −39.77 ± 32.91
   FEF~25--75~ in women                                                                                   −68.89 ± 58.88
   FEF~25--75~ in men                                                                                     −74.11 ± 70.24
  Genotype distribution                                                                                   
   *p53* P72R, rs1042522                                                                                  
    GG                                                                                                    2,407
    CG                                                                                                    1,637
    CC                                                                                                    282
   *p21* S31R, rs1801270                                                                                  
    CC                                                                                                    3,701
    CA or AA[c](#tfn4-ehp-117-1420){ref-type="table-fn"}                                                  625
   *CCND1* P242P, rs9344                                                                                  
    GG                                                                                                    1,211
    GA                                                                                                    2,140
    AA                                                                                                    975
   *CCND1* −7006G\>C, rs667515                                                                            
    GG                                                                                                    1,628
    GC                                                                                                    2,058
    CC                                                                                                    640
   Diplotype distribution[d](#tfn5-ehp-117-1420){ref-type="table-fn"}                                     
   *CCND1* haplotype 1 (rs667515, rs9344)                                                                 
    −/−                                                                                                   3,125
    GG/−                                                                                                  1,088
    GG/GG                                                                                                 113
   *CCND1* haplotype 2 (rs667515, rs9344)                                                                 
    −/−                                                                                                   1,251
    GA/−                                                                                                  2,150
    GA/GA                                                                                                 925
   *CCND1* haplotype 3 (rs667515, rs9344)                                                                 
    −/−                                                                                                   1,678
    CG/−                                                                                                  2,048
    CG/CG                                                                                                 600
   *CCND1* haplotype 4 (rs667515, rs9344)                                                                 
    −/−                                                                                                   4,239
    CA/−                                                                                                  84
    CA/CA                                                                                                 3

IQR, interquartile range.

PM~10~ (μg/m^3^) in the year before SAPALDIA1 minus PM~10~ in the year before SAPALDIA2.

Women, *n* = 2,293; men, *n* = 2,033.

Genotype distribution: *p21* CA, *n* = 594; *p21* AA, *n* = 31.

Diplo-type distribution is labeled as follows: −/−, none of the specific haplotype present; (*rs667515*, *rs9344*)/− (e.g., GG/−), one of the specific haplotypes present; (*rs667515*, *rs9344*)/(*rs667515*, *rs9344*) (e.g., GG/GG), for two of the specific haplotypes present.

###### 

Effect modification by genotypes: association[a](#tfn6-ehp-117-1420){ref-type="table-fn"} of change in average home outdoor PM~10~ (per decrease of 10 μg/m^3^ between 1991 and 2002) with average annual decline in FEF~25--75~ (mL/year), by genotype status.

  Genotype                                                                              No.     Average annual FEF~25--75~ decline[b](#tfn7-ehp-117-1420){ref-type="table-fn"}   95% CI              *p*-Value   *p*~int~[c](#tfn8-ehp-117-1420){ref-type="table-fn"}
  ------------------------------------------------------------------------------------- ------- -------------------------------------------------------------------------------- ------------------- ----------- ------------------------------------------------------
  *p53* R72P; rs1042522                                                                                                                                                                                          
   GG                                                                                   2,407   17.37                                                                            8.95 to 25.78       \< 0.001    0.016~(codominant)~
   CG                                                                                   1,637   11.63                                                                            2.65 to 20.61       0.011       
   CC                                                                                   282     −4.33                                                                            −21.37 to 12.7      0.618       
  *p21* S31R; rs1801270                                                                                                                                                                                          
   CC                                                                                   3,701   12.72                                                                            5.35 to 20.1        0.001       0.115~(dominant)~
   CA or AA[d](#tfn9-ehp-117-1420){ref-type="table-fn"}                                 625     23.88                                                                            9.25 to 38.51       0.001       
   *CCND1* P242P; rs9344                                                                                                                                                                                         
   GG                                                                                   1,211   21.33                                                                            10.57 to 32.08      \< 0.001    0.017~(codominant)~
   AG                                                                                   2,140   13.72                                                                            5.38 to 22.06       0.001       
   AA                                                                                   975     6.00                                                                             −4.54 to 16.54      0.265       
  *CCND1* −7006G\>C; rs667515                                                                                                                                                                                    
   GG                                                                                   1,628   10.39                                                                            1.32 to 19.47       0.025       0.006~(recessive)~
   CG                                                                                   2,058   11.83                                                                            3.24 to 20.42       0.007       
   CC                                                                                   640     28.83                                                                            15.6 to 42.07       \< 0.001    
  *CCND1* haplotype 1 (rs667515, rs9344)[e](#tfn10-ehp-117-1420){ref-type="table-fn"}                                                                                                                            
   −/−                                                                                  3,125   13.67                                                                            5.99 to 21.34       \< 0.001    0.156~(recessive)~
   GG/−                                                                                 1,088   11.1                                                                             0.26 to 21.94       0.045       
   GG/GG                                                                                113     37.77                                                                            3.24 to 72.3        0.032       
  *CCND1* haplotype 2 (rs667515, rs9344)[e](#tfn10-ehp-117-1420){ref-type="table-fn"}                                                                                                                            
   −/−                                                                                  1,251   20.66                                                                            10.07 to 31.24      \< 0.001    0.022~(codominant)~
   GA/−                                                                                 2,150   13.75                                                                            5.34 to 22.15       0.001       
   GA/GA                                                                                925     6.08                                                                             −4.5 to 16.67       0.26        
  *CCND1* haplotype 3 (rs667515, rs9344)[e](#tfn10-ehp-117-1420){ref-type="table-fn"}                                                                                                                            
   −/−                                                                                  1,678   10.28                                                                            1.22 to 19.35       0.026       0.003~(recessive)~
   CG/−                                                                                 2,048   11.92                                                                            3.4 to 20.44        0.006       
   CG/CG                                                                                600     30.9                                                                             17.21 to 44.58      \< 0.001    
  *CCND1* haplotype 4 (rs667515, rs9344)[e](#tfn10-ehp-117-1420){ref-type="table-fn"}                                                                                                                            
   −/−                                                                                  4,239   13.52                                                                            6.22 to 20.82       \< 0.001    0.434~(codominant)~
   CA/−                                                                                 84      −1.4                                                                             −39.67 to 36.88     0.943       
   CA/CA                                                                                3       −11.8                                                                            −468.22 to 444.62   0.96        

Covariates were age, age^2^, sex, height, parental smoking, sine and cosine function of day of examination to control for seasonal effects, level of education at SAPALDIA1, change in level of education, Swiss nationality, self-reported occupational exposure to dust and occupational exposure to fumes at SAPALDIA1 and SAPALDIA2 (yes/no), smoking status at SAPALDIA2 (never, former, or current), pack-years up to SAPALDIA1, pack-years between SAPALDIA1 and -2, cigarettes per day at SAPALDIA1 and -2, atopy, BMI at SAPALDIA1, change in BMI, interaction between the two BMI variables, and baseline PM~10~ exposure.

Positive estimates indicate attenuation of lung function decline associated with PM~10~ decrease. Negative estimates indicate acceleration of lung function decline with PM~10~ decrease.

*p*-Value for interaction between change in home outdoor exposure of PM~10~ and genotype parameterized in three different genetic models. The *p*~int~ values presented here represent the most significant (lowest) *p*-value obtained from the three different genetic models. Bonferroni significance level for 12 comparisons \[three respiratory function tests (FVC, FEV~1~, FEF~25--75~) × times four association tests\], *p* = 0.00417.

Genotype distribution: *p21* CA, *n* = 594; *p21* AA, *n* = 31.

Diplotype distribution is labeled as follows: −/−, none of the specific haplotype present; (*rs667515*, *rs9344*)/− (e.g., GG/−), one of the specific haplotypes present; (*rs667515*, *rs9344*)/(*rs667515*, *rs9344*) (e.g., GG/GG), for two of the specific haplotypes present.
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The SAPALDIA Team.
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  ----------------------------------------- --------------------------------------------
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  Scientific team at coordinating centers   
   P.O. Bridevaux                           Pneumology
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   J. Dratva                                Epidemiology
   D. Felber Dietrich                       Cardiology
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   G.A. Thun                                Genetic and molecular biology
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